Current studies have demonstrated that imatinib inhibits bleomycin-induced IPF [67, 68], and the mechanism of action is closely related to inhibition of lung FMT and inhibition of the ECM produced by PDGF and TGF-β signaling [69]. Here, TGFB1 is linked to idiopathic pulmonary fibrosis.